AFMD

Affimed NV News

FREE AFMD REPORT

Company Name Stock Ticker Symbol Market Type
Affimed NV AFMD NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
0.03 2.52% 1.22 20:00:00
Open Price Low Price High Price Close Price Prev Close
1.19 1.17 1.235 1.20 1.19
more quote information »

Recent News

Date Time Source Heading
1/26/20237:21IHNWFeaturedUCASU jump-starts its plan of NASDAQ or NYSE up-listing in 2023
1/09/202306:30GLOBEAffimed Reports on Corporate Progress and Provides..
12/22/202206:30GLOBEAffimed Announces Approval of Clinical Trial Application in..
12/12/202214:46TRMNAffimed Plunges after Detailing New Plans
12/12/202211:26TRMNWells Fargo Reaffirms Their Buy Rating on Affimed (AFMD)
12/12/202210:00GLOBEAffimed Presents Updated Data for AFM28 Demonstrating..
12/12/202208:16EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
12/12/202206:05TRMNAffimed (AFMD) Receives a Buy from Berenberg Bank
12/10/202215:00GLOBEAffimed Reports Topline Data from AFM13 Monotherapy Phase 2..
12/10/202214:20GLOBEAffimed Provides Updated Clinical Data from Phase 1/2 Study..
12/01/202216:05GLOBEAffimed to Host Investor Event Highlighting AFM13 Clinical..
11/17/202223:35TRMNSVB Securities Sticks to Its Buy Rating for Affimed (AFMD)
11/15/202206:47EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
11/15/202206:30GLOBEAffimed Reports Third Quarter 2022 Financial Results..
11/14/202206:05TRMNAffimed (AFMD) Receives a Buy from Berenberg Bank
11/07/202215:55TRMNAffimed (AFMD) Gets a Buy from SVB Securities
11/07/202208:05GLOBEAffimed Provides Data Update from Two Phase 1/2a Trials with..
11/04/202206:30GLOBEAffimed to Report Third Quarter 2022 Financial Results &..
11/04/202206:05TRMNBerenberg Bank Keeps Their Buy Rating on Affimed (AFMD)
11/03/202209:24EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
11/03/202209:15GLOBEAffimed and Artiva Biotherapeutics Announce Partnership to..
11/03/202209:05GLOBEAffimed Announces Presentation of Phase 1/2 Data from AFM13..
11/01/202206:30GLOBEAffimed to Present at the 2022 Jefferies London Healthcare..
10/05/202208:05GLOBEAffimed Announces Two Clinical Update Presentations on its..
9/01/202206:30GLOBEAffimed to Present at Upcoming Investor Conferences
8/16/202204:47TRMNSVB Securities Sticks to Their Buy Rating for Affimed (AFMD)
8/12/202206:05TRMNAffimed (AFMD) Gets a Buy from Berenberg Bank
8/11/202206:30GLOBEAffimed Reports Second Quarter 2022 Financial Results and..
8/04/202206:30GLOBEAffimed to Report Second Quarter 2022 Financial Results &..
6/30/202216:00GLOBEAffimed Establishes Scientific Advisory Board
6/23/202216:30TRMNSVB Securities Thinks Affimed’s Stock is Going to Recover
6/23/202207:29EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
6/10/202210:31GLOBEAffimed Presents Preclinical Data of Novel Innate Cell..
6/01/202206:54EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
6/01/202206:30GLOBEAffimed Reports First Quarter 2022 Financial Results and..
5/26/202217:05GLOBEAffimed Highlights Trial Designs of Three AFM24 Ongoing..
5/26/202206:30GLOBEAffimed to Present at the 2022 Jefferies Healthcare..
5/24/202206:30GLOBEAffimed Announces Annual General Meeting of Shareholders
5/16/202208:00GLOBEAffimed Presents Data on Innate Cell Engagers AFM24 and..
5/12/202210:31GLOBEAffimed to Present Preclinical Data Demonstrating Cytotoxic..
5/09/202215:25EDGARStatement of Ownership (sc 13g)
5/06/202216:02GLOBEAffimed Provides Update on ASCO AFM13-104 Oral Presentation
5/01/202212:42TRMNLeerink Partners Thinks Affimed’s Stock is Going to Recover
4/27/202217:20GLOBECORRECTING and REPLACING -- Affimed N.V.
4/27/202216:05GLOBEAffimed Announces Clinical Update and Trial in Progress..
4/21/202206:10EDGARStatement of Ownership (sc 13g)
4/18/202216:07EDGARReport of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16..
4/18/202211:28GLOBEAffimed Announces Closing of Public Offering of Common..
4/14/202216:18EDGARProspectus Filed Pursuant to Rule 424(b)(5) (424b5)
4/12/202222:02GLOBEAffimed Announces Pricing of Upsized $90 Million Public..
4/12/202216:02GLOBEAffimed Announces Proposed Public Offering of Common Shares